In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 641 ( 2022-04-20)
Abstract:
Immune checkpoint blockade benefits a subset of patients with clear cell renal cell carcinoma (ccRCC), but accumulation of immune-suppressive myeloid cells can lead to treatment resistance. The combination of sitravatinib, a tyrosine kinase inhibitor shown to decrease immune-suppressive myeloid cells, with immune checkpoint blockade might therefore improve clinical outcomes. Here, Msaouel and colleagues conducted a phase 1-2 clinical trial using a late-onset efficacy-toxicity design to identify an optimal dose of sitravatinib in combination with nivolumab in immunotherapy-naïve patients with advanced ccRCC. The combination led to a response rate of 35.7% and an 88.1% disease control rate, with a reduction in immune-suppressive myeloid cells in the peripheral blood and the tumor microenvironment. Phase 3 studies using this combination are now underway.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abm6420
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink